Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 2 - The Real Truth

Best Strong Buy Stocks for a Stock Picker's Market

Current market conditions have folks seeking out sturdy investment opportunities. These Strong Buy stocks are a good place to start.

Kiplinger · Aug 17, 2023

What's behind shortages of Adderall, Ozempic and other meds?

Drug shortages are growing in the United States, and experts see no clear path to resolving them

The Independent UK · Apr 30, 2023

Adderall shortage puts U.S. on brink of public health crisis

A rise in demand for Adderall has triggered a shortage of the drug.

Axios · Nov 15, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

BLRX: September NDA

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT

Benzinga · Aug 23, 2022

Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions

National trade union of medical representatives cites paracetamol to make a case against unethical marketing practices of pharma companies

The Hindu · Aug 20, 2022

Saudi Arabia, US Sign 18 Agreements in Energy, Other Areas

Saudi Arabia and the United States signed 18 partnership agreements in fields including energy, communications, space and healthcare during a visit by US President Joe Biden. The agreements include deals with US aerospace and defense firms Boeing and Raytheon, as well as healthcare companies Medtronic, Digital Diagnostics, and IQVIA, according…

Asharq Al-Awsat · Jul 16, 2022

Investors Seem To Be Unmoved By IQVIA's Street Lagging Estimates, Q1 Surpass Expectations

IQVIA Holdings Inc (NYSE:IQV) posted Q1 sales of $3.57 billion, up 4.7% on a reported basis and 6.8% at constant currency (CC), slightly above the consensus of $3.55 billion. Technology & Analytics Solutions revenue increased 6.8% (9.8% CC) to $1.44 billion. Research & Development Solutions (R&DS) sales reached $1.93 billion, +3.5% (4.7%…

Benzinga · Apr 27, 2022

Read news from The Economist, FT, and more,
with one subscription

3 Beaten-Down Growth Stocks to Snatch Up in Q2 2022

Despite no clarity on when the Russia-Ukraine war will end, surging inflation, and logistical hindrances, the U.S. economy looks sufficiently resilient to weather the crises. Given this backdrop, we think shares of beaten-down growth stocks IQVIA (IQV), West Pharmaceutical (WST), and Synopsys (SNPS) could soar in price in the coming…

StockNews.com · Apr 11, 2022

1 2

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.